References
- Beuvery EC, van Delft RW, Tiesjema RH, Nagel J. The enzyme-linked immunosorbent assay of meningococcal and some related Escherichia coli polysaccharides. J Biol Stand 1983; 11:195-204; PMID:6350305; http://dx.doi.org/10.1016/S0092-1157(83)80006-7
- Afshar M, Esmaily F, Aminian M, Asli E, Haadi A, Torabi M, Hatami A. A study on haemophilus influenzae type b growth rate and capsule production in different media. Archives of Razi Institute 2012; 67:7-12.
- Saydam M, Rigsby P, Mawas F. A novel Enzyme-Linked Immuno-Sorbent Assay (ELISA) for the quantification of total and free polysaccharide in Haemophilus influenzae b-Tetanus toxoid conjugate vaccines in monovalent and combined vaccine formulations. Biologicals 2014; 42:29-33; PMID:24200313; http://dx.doi.org/10.1016/j.biologicals.2013.10.002
- Sutton A, Vann WF, Karpas AB, Stein KE, Schneerson R. An avidin-biotin based ELISA for quantitation of antibody to bacterial polysaccharides. J Immunol Methods 1985; 82:215-24; PMID:3900215; http://dx.doi.org/10.1016/0022-1759(85)90353-9
- Kreeftenberg JG, Hamidi A. Annex 5. Lessons learned in the transfer of Hib conjugate vaccine technology and the consequences for access to this vaccine in developing countries. World Health Organization (WHO); 2004. Report No.: WHO/IVB/04.21. Available from: http://whqlibdoc.who.int/hq/2004/WHOIVB 04.21(302KB).pdf.
- Arvas A, Gur E, Bahar H, Torun MM, Demirci M, Aslan M, Kocazeybek B. Haemophilus influenzae type b antibodies in vaccinated and non-vaccinated children. Pediatr Int 2008; 50:469-73; PMID:19143969; http://dx.doi.org/10.1111/j.1442-200X.2008.02591.x
- Beurret M, Hamidi A, Kreeftenberg H. Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries. Vaccine 2012; 30:4897-906; PMID:22683521; http://dx.doi.org/10.1016/j.vaccine.2012.05.058
- Ashwell G. Colorimetric analysis of sugars. Methods Enzymol 1957; 3:73-105; http://dx.doi.org/10.1016/S0076-6879(57)03350-9
- Lemercinier X, Jones C, Corbel MJ, Yost S. Analytical procedures used in the control of bacterial glycoconjugate vaccines. Pharm Pharmacol Commun 1997; 3:19-23.
- Cuervo ML, Pérez LR, Oviedo M, Costa L, Perdomo V. Relationships among physico-chemical and biological tests for a synthetic Hib-TT conjugate vaccine. Vaccine 2007; 25:194-200; PMID:17161239; http://dx.doi.org/10.1016/j.vaccine.2005.05.041
- WHO Expert Committee on Biological Standardization. Forty-ninth report. Annex 1. Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines. WHO Technical Report Series 2000; 897:27-60.
- Haemophilus type b conjugate vaccine. Eur Pharmacopoeia 2005; 5.0: 662-4.
- Chu C, Schneerson R, Robbins JB, Rastogi SC. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun 1983; 40:245-56; PMID:6601061
- Gupta RK, Anderson R, Cecchini D, Rost B, Griffin P Jr., Benscoter K, Xu J, Montanez-Ortiz L, Siber GR. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines. Dev Biol Stand 1996; 86:283-96; PMID:8785957
- Siber GR, Anderson R, Habafy M, Gupta RK. Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines. Vaccine 1995; 13:525-31; PMID:7483772; http://dx.doi.org/10.1016/0264-410X(94)00042-L
- Hamidi A, Beurret M. De Staat der Nederlanden, Process for producing a capsular polysaccharide for use in conjugate vaccines. US 7 582 459; 2004.
- Hendriksen CF, van der Gun JW, Marsman FR, Kreeftenberg JG. The use of the in vitro toxin binding inhibition (ToBI) test for the estimation of the potency of tetanus toxoid. Biologicals 1991; 19:23-9; PMID:2049173; http://dx.doi.org/10.1016/1045-1056(91)90020-K
- van Alphen L, Eijk P, Käyhty H, van Marle J, Dankert J. Antibodies to Haemophilus influenzae type b polysaccharide affect bacterial adherence and multiplication. Infect Immun 1996; 64:995-1001; PMID:8641812
- Toraño G, Toledo ME, Baly A, Fernandez-Santana V, Rodriguez F, Alvarez Y, Serrano T, Musachio A, Hernandez I, Hardy E, et al. Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b in human adult volunteers. Clin Vaccine Immunol 2006; 13:1052-6; PMID:16960118; http://dx.doi.org/10.1128/CVI.00144-06
- Chu C, Schneerson R, Robbins JB, Rastogi SC. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun 1983; 40:245-56; PMID:6601061
- Yang J, Wang H, Zhang H. One-pot synthesis of silver nanoplates and charge-transfer complex nanofibers. J Phys Chem C 2008; 112:13065-9; http://dx.doi.org/10.1021/jp802604d
- Holland VR, Saunders BC, Rose FL, Walpole AL. A safer substitute for benzidine in the detection of blood. Tetrahedron 1974; 30:3299; http://dx.doi.org/10.1016/S0040-4020(01)97504-0